A clinical trial will study investigational therapies in people at the earliest stages of systemic sclerosis (SSc), before irreversible organ damage has occurred. Contract research organization Indero and the World Scleroderma Foundation (WSF) are partnering on the trial, called WSF SHIELD. It will test multiple investigational therapies in…
Discussion
Off-label treatment with JAK inhibitors appeared to keep lung function stable and reduce skin thickening, joint pain, and swelling in a small real-world study of systemic sclerosis (SSc). They also caused some side effects and their use needs further confirmation in larger controlled studies, researchers wrote. The study, “…
Discussion
People with scleroderma who are triple autoantibody-negative — meaning they don’t have three common disease-associated antibodies — are more likely to experience muscle damage and lung disease than others with the rare condition, a new study shows. Conversely, data indicate that patients negative for the three antibodies are less…
Becoming educated and informed about scleroderma is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your scleroderma journey.
There is no cure for scleroderma yet, but here you can find more information about current therapeutic approaches, as well as experimental treatments that are in the pipeline.
Get regular updates to your inbox.
